Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
ImmunityBio, Inc.
Next earnings ≈ Aug 6, 2026 · est. from filing cadence
Last earnings -7.4% on 2026-05-07
Revenue grew 668.3% YoY; but unprofitable (net margin -310.2%).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
ImmunityBio, Inc. shows $113M in FY2025 revenue (+668.3% YoY), a -310.2% net margin, and 70.2% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001326110, latest 10-Q filed 2026-05-07) · EODHD · rules-based read · as of 6/18/2026, 12:36:21 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $240K | $622K | $14.7M | $113M |
| Gross profit | — | — | — | — | — |
| Operating income | -$330M | -$351M | -$362M | -$344M | -$256M |
| Net income | -$347M | -$417M | -$583M | -$414M | -$351M |
| Diluted EPS | -$0.89 | -$1.04 | -$1.15 | -$0.62 | -$0.38 |
| Net margin | — | -173569.6% | -93761.4% | -2804.8% | -310.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
Last 90 days: 0 open-market buys · 1 sale
| 2026-06-04 | Simon Barry J. Director | Sell | 23.0K @ $7.18 | $165K |
| 2026-03-31 | SOON-SHIONG PATRICK See remarks | Acquired (C) | 4.61M @ $5.43 | $25.0M |